411 related articles for article (PubMed ID: 10884345)
1. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
2. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
Heddle JG; Lu T; Zhao X; Drlica K; Maxwell A
J Mol Biol; 2001 Jun; 309(5):1219-31. PubMed ID: 11399091
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
5. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
Barnard FM; Maxwell A
Antimicrob Agents Chemother; 2001 Jul; 45(7):1994-2000. PubMed ID: 11408214
[TBL] [Abstract][Full Text] [Related]
6. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Freudenreich CH; Chang C; Kreuzer KN
Cancer Res; 1998 Mar; 58(6):1260-7. PubMed ID: 9515814
[TBL] [Abstract][Full Text] [Related]
8. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions.
Sissi C; Perdonà E; Domenici E; Feriani A; Howells AJ; Maxwell A; Palumbo M
J Mol Biol; 2001 Aug; 311(1):195-203. PubMed ID: 11469868
[TBL] [Abstract][Full Text] [Related]
9. Linker insertion mutagenesis of Drosophila topoisomerase II. Probing the structure of eukaryotic topoisomerase II.
Lee MP; Hsieh TS
J Mol Biol; 1994 Jan; 235(2):436-47. PubMed ID: 8289273
[TBL] [Abstract][Full Text] [Related]
10. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
11. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
12. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
13. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
14. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
Jiang X
Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
[TBL] [Abstract][Full Text] [Related]
15. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
16. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
18. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
19. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
20. The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.
Suda N; Ito Y; Imai T; Kikumori T; Kikuchi A; Nishiyama Y; Yoshida S; Suzuki M
Nucleic Acids Res; 2004; 32(5):1767-73. PubMed ID: 15026536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
